AnaptysBio, Inc.
ANAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $91,280 | $17,157 | $10,287 | $63,175 |
| % Growth | 432% | 66.8% | -83.7% | – |
| Cost of Goods Sold | $163,840 | $132,283 | $88,798 | $98,496 |
| Gross Profit | -$72,560 | -$115,126 | -$78,511 | -$35,321 |
| % Margin | -79.5% | -671% | -763.2% | -55.9% |
| R&D Expenses | $163,840 | $139,622 | $88,798 | $98,496 |
| G&A Expenses | $42,389 | $41,946 | $36,643 | $21,493 |
| SG&A Expenses | $42,389 | $41,946 | $36,643 | $21,493 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$163,840 | -$132,283 | -$88,798 | -$98,496 |
| Operating Expenses | $42,389 | $49,285 | $36,643 | $21,493 |
| Operating Income | -$114,949 | -$164,411 | -$115,154 | -$56,814 |
| % Margin | -125.9% | -958.3% | -1,119.4% | -89.9% |
| Other Income/Exp. Net | -$30,279 | $788 | -$13,546 | -$982 |
| Pre-Tax Income | -$145,228 | -$163,623 | -$128,700 | -$57,796 |
| Tax Expense | $3 | -$4 | $24 | $0 |
| Net Income | -$145,231 | -$163,619 | -$128,724 | -$57,796 |
| % Margin | -159.1% | -953.7% | -1,251.3% | -91.5% |
| EPS | -5.12 | -6.08 | -4.57 | -2.11 |
| % Growth | 15.8% | -33% | -116.6% | – |
| EPS Diluted | -5.12 | -6.08 | -4.57 | -2.11 |
| Weighted Avg Shares Out | 28,382 | 26,924 | 28,165 | 27,431 |
| Weighted Avg Shares Out Dil | 28,382 | 26,924 | 28,165 | 27,431 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,794 | $18,873 | $7,550 | $431 |
| Interest Expense | $50,087 | $18,083 | $21,108 | $1,450 |
| Depreciation & Amortization | $2,397 | $652 | $2,335 | $2,090 |
| EBITDA | -$92,744 | -$156,420 | -$105,257 | -$55,706 |
| % Margin | -101.6% | -911.7% | -1,023.2% | -88.2% |